Ara
Toplam kayıt 23, listelenen: 1-10
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
(Sage Publications, 2022)
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide – with an estimated global prevalence of 37%. Different from nonalcoholic fatty liver disease (NAFLD), which ...
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
(Elsevier, 2022)
Background & Aims: Currently available non-invasive tests, including fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM by VCTE), are highly effective at excluding advanced fibrosis (AF) (F ≥3) or cirrhosis in ...
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
(AME Publishing Company, 2023)
Background: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In ...
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight
(Wiley, 2023)
The obesity epidemic is globally driving the increased prevalence of non-alcoholic fatty liver disease (NAFLD), and the vast majority of patients with NAFLD are either overweight or obese.
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
(Lippincott Williams & Wilkins, 2023)
Background:Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may ...
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
(Kare Publishing, 2023)
Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan (R) is used for follow-up of fibrosis and steatosis. This single -cen-ter ...
The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients
(Kare Publishing, 2023)
Background and Aim: This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2.Materials ...
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
(Elsevier, 2022)
Background & Aims: Non-invasive tests (NITs) offer a practical solution for advanced fibrosis identification in non-alcoholic
fatty liver disease (NAFLD). Despite increasing implementation, their use is not standardised, ...
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
(Kare Publishing, 2023)
Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
(Wolters Kluwer Medknow Publications, 2023)
Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective
treatment for NASH. This randomized, multicenter, double-blind, phase 2b
study ...